Rubicon Organics Reports Q3 2024 Financial and Operating Results
- Delivered a record net revenue of $13.5 million for Q3 2024, a 34% increase year-over-year, and $34.5 million for the first nine months of 2024, a 15% increase year-over-year.
- Adjusted EBITDA1 of $2.0 million for the three months ended September 30, 2024
- Operating cash flow of $0.9 million for the three months ended September 30, 2024
- #1 premium licenced producer across all categories2
VANCOUVER, British Columbia, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Rubicon Organics Inc. (TSXV: ROMJ) (OTCQX: ROMJF) (“Rubicon Organics” or the “Company”), a licensed producer focused on cultivating and selling organic certified and premium cannabis, today reported its financial results for the three and nine months ended September 30, 2024 (“Q3 2024”). All amounts are expressed in Canadian dollars.
“Rubicon Organics record net revenue for both Q3 and year-to-date 2024 reflects our strength and position as Canada’s leading premium House of Brands. Rubicon Organics continues to innovate and expand our product offerings, solidifying a strong market share in premium flower, pre-rolls, edibles, and more. I’m particularly proud of the success of our 2024 vape launch, which has already achieved 55% distribution in just six months. Looking ahead, we expect to drive further growth in Canada and beyond, as we intend for new market entry in 2025.”
"Rubicon Organics’ financial results for Q3 2024 reflect our strong operational execution and strategic focus. With a record-high net revenue of $13.5 million for the quarter and $34.5 million for the nine-month period, we have demonstrated our ability to achieve growth despite the challenges in the market. Our commitment to disciplined financial management has resulted in positive adjusted EBITDA for eight out of the last nine quarters. We also anticipate finalizing our debt re-financing before the end of the year paving the way for the Company’s next five years of growth," said Janis Risbin, CFO.
________________________1 Adjusted EBITDA is a non-GAAP measure that is calculated as earnings (losses) from operations before interest, tax, depreciation and amortization, share-based compensation expense, and fair value changes. Included in Adjusted EBITDA in the nine months ended September 30, 2024 is $0.6 million of one-time costs incurred for the ERP implementation project. See Non-GAAP Financial Measures for details on the Adjusted EBITDA calculation.2 Hifyre data for premium products covering flower, pre-rolled products, concentrates, edibles, topicals, and vapes for the twelve months ended September 30, 2024
Q3 2024 and Subsequent Highlights:
For the three and nine months ended September 30, 2024
- Net revenue of $13.5 million (34% increase from Q3 2023) and $34.5 million (15% increase from Q3 2023) for the three and nine months ended September 30, 2024.
- Gross profit before fair value adjustments of $4.4 million (35% increase from Q3 2023) and $10.2 million (6% decrease from Q3 2023) for the three and nine months ended September 30, 2024.
- Adjusted EBITDA1 gain of $2.0 million and $2.4 million compared to $1.1 million and $3.1 million in Q3 2023, for the three and nine months ended September 30, 2024.
- Cash provided by operating activities of $0.9 million for the three months ended September 30, 2024.
- #1 premium licenced producer across all categories3 with 6.4% market share, up from 5.1%4.
- 2.0%5 national market share of flower and pre-rolls for the three and nine months ended September 30, 2024.
- 5.7%6 and 6.2%7 national market share of premium flower and pre-rolls for the three and nine months ended September 30, 2024.
- Wildflower™ is the #1 topical brand in Canada with market share of 27.8%8 for the nine months ended September 30, 2024.
- 28.5%9 and 27.2%10 national market share of premium edibles for the three and nine months ended September 30, 2024.
- Launch of full spectrum extract vapes in Alberta, BC, and Ontario with four SKUs in market.
________________________3 Hifyre data for premium products covering flower, pre-rolled products, concentrates, edibles, topicals, and vapes for the twelve months ended September 30, 20244 Hifyre data for premium products covering flower, pre-rolled products, concentrates, edibles, topicals, and vapes for the nine months ended September 30, 20235 Hifyre data for flower & pre-rolled products covering three and nine months ended September 30, 20246 Hifyre data for premium flower & pre-rolled products covering three months ended September 30, 20247 Hifyre data for premium flower & pre-rolled products covering nine months ended September 30, 20248 Hifyre data for topical products covering nine months ended September 30, 20249 Hifyre data for premium edible products covering three months ended September 30, 202410 Hifyre data for premium edible products covering nine months ended September 30, 2024
2024 Results of Operations:
| Three months ended | Nine months ended | |||||||
| September 30,2024$ | September 30,2023$ | September 30,2024$ | September 30,2023$ | |||||
| Net revenue | 13,499,282 | 10,041,746 | 34,495,396 | 30,123,479 | ||||
| Production costs | 2,897,890 | 2,797,037 | 8,522,534 | 8,067,975 | ||||
| Inventory expensed to cost of sales | 6,013,707 | 3,806,971 | 14,960,189 | 10,657,979 | ||||
| Inventory written off or provided for | 209,770 | 194,798 | 788,773 | 525,401 | ||||
| Gross profit before fair value adjustments | 4,377,915 | 3,242,940 | 10,223,900 | 10,872,124 | ||||
| Fair value adjustments to cannabis plants, inventory sold, and other charges | (500,324 | ) | (1,309,266 | ) | 62,718 | (1,776,209 | ) | |
| Gross profit | 3,877,591 | 1,933,674 | 10,286,618 | 9,095,915 | ||||
| As at: | September 30,2024$ | December 31,2023$ | ||
| Cash and cash equivalents | 9,601,162 | 9,784,190 | ||
| Working capital † | 10,643,402 | 10,132,089 |
† Working capital as at September 30, 2024 includes $10.9 million current portion of loans and borrowings. The Company is currently in discussions with the debenture holder and other lenders to extend the term of the existing agreement or to enter into a new loan agreement anticipated to be finalised before the end of the year.
2024 Outlook
Brand and Product Development
Our strategy is founded on a strong premium house of brands, highly regarded by both budtenders and consumers alike. Guided by consumer research, we continually innovate our products to anticipate market trends. Our commitment to quality and excellence is evident throughout all areas of our business, seeking to deliver products and services that consistently meet the highest quality standards.
Launch into Vape Category
Rubicon launched into the vape category with our 1964 Supply Co™ brand. The introduction of vapes strategically aligns with our market expansion strategy and offers substantial growth prospects. The vape market has demonstrated robust growth over recent years and trends in Canada and the US support the vape category's increasing prominence, rivaling or surpassing traditional flower products.
Using our Delta grown genetics and supplementing with biomass of the same genetics grown at partners, we launched Comatose and Blue Dream Full Spectrum Extract (“FSE”) resin vapes in Ontario, BC, and Alberta in May 2024. Following strong demand, we launched new cultivars, with GLTO #41 in late July 2024 and White Rainbow in October 2024. We anticipate launching a fifth vape SKU in market by the end of 2024.
In line with our approach to the live rosin edibles we launched under the brand in 2023, we are focused on delivering products that maintain a competitive edge through superior quality, right price to value ratio leveraging our established and reputable brands. We are confident that by capitalizing on this opportunity, over time we can achieve comparable financial success with our vape offerings as we have with our flower business.
Wildflower™’s Leadership in Cannabis Wellness
Wildflower™'s prominence in the cannabis wellness sector is driven by its notable topical products. The Company has expanded the brand to adjacent categories, including edibles, oils, and capsules designed to address specific wellness needs such as sleep, pain relief, and anxiety reduction. While we expect more competition to enter the topical and wellness category, we are expanding the brand into other categories and anticipate steady growth and momentum behind the daily wellness consumer.
Launch of New Genetics
Rubicon plans to continue to launch new and novel genetics into its Simply Bare™ Organic and 1964 Supply Co™ brands to continue leadership in the premium cannabis market. Launches in 2024 include BC Organic Zookies, BC Organic Power Mintz, BC Organic Fruit Loopz, and BC Organic Pineapple Sour under the Simply Bare™ Organic brand. Blue Dream, Stinky Pinky and LA Kush Cake have been launched under the 1964 Supply Co™ brand in 2024 with Sour Tangie expected to launch before the end of the year.
Growth from Solid Business Fundamentals
Consistent quality and systematic delivery to our customers, including the provincial distributors and retailers, and consumers to meet their needs is imperative to be successful in the Canadian cannabis industry. In 2024 we are investing in an Enterprise Resource Planning (“ERP”) system which is necessary for our business to deliver more growth in future and reduce reliance on key people within our internal systems. Project costs are estimated to reach $1 million, with $0.6 million incurred in the first nine months of 2024. While a resource intensive process, this ERP implementation readies our business for growth in the future.
Financial
We believe that our commitment to cannabis quality, strategic brand positioning, diverse product portfolio, and committed team will position us as one of the premier cannabis companies in Canada. For 2024, we continue to anticipate year over year growth in net revenue, supported by modest increases in our cost base, excluding the impact of the ERP implementation occurring across 2024, thereby enhancing our operating leverage. While we expect growth in 2024, we also anticipate that much of the growth will come from our branded products that are produced using external capacity and thereby deliver lower gross margin than our current mix. Furthermore, we anticipate continued fierce competition in the distressed Canadian cannabis industry, leading to the maintenance or growth of value and standard pricing tiers, rather than premium price tiers. Notwithstanding these pressures, we expect to deliver continued operating positive cash flow in the year ahead and plan to refinance our debt to a longer-term mortgage facility before the end of 2024.
Conference Call
The Company will be hosting a conference call to discuss Q3 2024 results on Thursday, November 14, 2024. Conference call details are as follows:
| Time: | 7:00 AM PT / 10:00 AM ET |
| Conference ID: | 86375 |
| Local dial-in: | +1 (289) 514 5100 |
| Toll Free N. America: | +1 (800) 717 1738 |
| Webcast: | https://onlinexperiences.com/Launch/QReg/ShowUUID=A9E9405C-21D9-4072-B6D5-2CE5F6ACE8DB |
ABOUT RUBICON ORGANICS INC.
Rubicon Organics Inc. is the global brand leader in premium organic cannabis products. The Company is vertically integrated through its wholly owned subsidiary Rubicon Holdings Corp, a licensed producer. Rubicon Organics is focused on achieving industry leading profitability through its premium cannabis flower, product innovation and brand portfolio management, including three flagship brands: its super-premium brand Simply Bare™ Organic, its premium brand 1964 Supply Co™, and its cannabis wellness brand Wildflower™ in addition to the Company’s mainstream brand Homestead Cannabis Supply™.
The Company ensures the quality of its supply chain by cultivating, processing, branding and selling organic certified, sustainably produced, super-premium cannabis products from its state-of-the-art glass roofed facility located in Delta, BC, Canada.
CONTACT INFORMATION
Margaret BrodieCEOPhone: +1 (437) 929-1964Email: ir@rubiconorganics.com
The TSX Venture Exchange or its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) does not accept responsibility for the adequacy or accuracy of this press release.
Non-GAAP Financial Measures
This press release contains certain financial performance measures that are not recognized or defined under IFRS (“Non-GAAP Measures”) including, but not limited to, “Adjusted EBITDA”. As a result, this data may not be comparable to data presented by other companies.
The Company believes that these Non-GAAP Measures are useful indicators of operating performance and are specifically used by management to assess the financial and operational performance of the Company as well as its liquidity. Accordingly, they should not be considered in isolation nor as a substitute for analysis of our financial information reported under IFRS. For more information, please refer to the “Selected Financial Information” section in the MD&A for the year ended December 31, 2023, which is available on SEDAR+ at www.sedarplus.ca.
Adjusted EBITDA
Below is the Company’s quantitative reconciliation of Adjusted EBITDA calculated as earnings (losses) from operations before interest, tax, depreciation and amortization, share-based compensation expense, and fair value changes. The following table presents the Company’s reconciliation of Adjusted EBITDA to the most comparable IFRS financial measure for the three and nine months ended September 30, 2024.
| Three months ended | Nine months ended | |||||||
| September 30,2024 | September 30,2023 | September 30,2024 | September 30,2023 | |||||
| $ | $ | $ | $ | |||||
| Profit / (Loss) from operations | 157,675 | (1,507,718 | ) | (1,462,244 | ) | (1,972,611 | ) | |
| IFRS fair value accounting related to cannabis plants and inventory | 500,324 | (1,309,266 | ) | (62,718 | ) | (1,776,209 | ) | |
| Depreciation and amortization | 809,602 | 810,633 | 2,418,231 | 2,330,643 | ||||
| Share-based compensation expense | 495,994 | 529,742 | 1,506,274 | 944,268 | ||||
| Adjusted EBITDA | 1,963,595 | 1,141,923 | 2,399,543 | 3,078,509 | ||||
‡ Included in Adjusted EBITDA in the nine months ended September 30, 2024 is $0.6 million of one-time costs incurred for the ERP implementation project.
Cautionary Statement Regarding Forward Looking Information
This press release contains forward-looking information within the meaning of applicable securities laws. All statements that are not historical facts, including without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs of future performance, statements regarding Rubicon Organics' goal of achieving industry leading profitability are "forward-looking statements". Forward-looking information can be identified by the use of words such as “will” or variations of such word or statements that certain actions, events or results "will" be taken, occur or be achieved.
Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward looking statements. The forward-looking information in this press release is based upon certain assumptions that management considers reasonable in the circumstances, including the impact on revenue of new products and brands entering the market, and the timing of achieve Adjusted EBITDA1 profitability and cashflow positive. Risks and uncertainties associated with the forward looking information in this press release include, among others, dependence on obtaining and maintaining regulatory approvals, including acquiring and renewing federal, provincial, local or other licenses and any inability to obtain all necessary governmental approvals licenses and permits for construction at its facilities in a timely manner; regulatory or political change such as changes in applicable laws and regulations, including bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; Rubicon Organics' limited operating history and lack of historical profits; reliance on management; and the effect of capital market conditions and other factors on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with customers and suppliers; and those factors identified under the heading "Risk Factors" in Rubicon Organic’s annual information form dated March 27, 2024 filed with Canadian provincial securities regulatory authorities.
These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements. Although Rubicon Organics has attempted to identify important risk factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. Rubicon Organics assumes no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, new information or for any other reason except as required by law.
We have made numerous assumptions about the forward-looking statements and information contained herein, including among other things, assumptions about: optimizing yield, achieving revenue growth, increasing gross profit, operating cashflow and Adjusted EBITDA1 profitability. Even though the management of Rubicon Organics believes that the assumptions made, and the expectations represented by such statements or information are reasonable, there can be no assurance that the forward-looking information will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. Investors are cautioned against undue reliance on forward-looking statements or information. Forward-looking statements and information are designed to help readers understand management's current views of our near and longer term prospects and may not be appropriate for other purposes. Rubicon Organics assumes no obligation to update any forward-looking statement, even if new information becomes available as a result of future events, changes in assumptions, new information or for any other reason except as required by law.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.